Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2023
2022
2021
2020
2019
2018
2017
Sep 27, 2023
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
➞
Sep 26, 2023
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador
➞
Sep 22, 2023
FDA Grants Fast Track Designation to 9MW3011
➞
Sep 06, 2023
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
➞
Sep 05, 2023
Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs
➞
Aug 28, 2023
Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines
➞
Jul 31, 2023
Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Morocco Market
➞
Jul 21, 2023
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
➞
Jul 17, 2023
Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
➞
Jul 14, 2023
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
➞
1
2
3
下一页